Iovance Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	158.13	115.69	114.89	231.73	78.23	67.33
Short-Term Investments	142.67	208.09	164.98	240.11	426.18	562.11
Cash & Short-Term Investments	300.8	323.78	279.87	471.85	504.41	629.44
Cash Growth	-24.32%	15.69%	-40.69%	-6.46%	-19.86%	104.97%
Receivables	66.76	69.34	0.15	-	-	-
Inventory	51.71	51.52	10.37	-	-	-
Prepaid Expenses	9.82	12.38	17.46	7.27	3.55	6.66
Total Current Assets	429.09	457.02	307.85	479.12	507.96	636.1
Property, Plant & Equipment	175.41	164.28	176.55	178.25	169.92	113.92
Long-Term Investments	-	-	-	-	91.59	-
Other Intangible Assets	285.21	282.4	229.26	-	-	-
Other Long-Term Assets	15.24	6.73	66.7	6.62	7.87	18.44
Total Assets	904.95	910.43	780.35	663.98	777.33	768.46
Accounts Payable	31.24	27.51	33.12	26.6	27.38	13.51
Accrued Expenses	82.91	75.19	66.97	45.79	51.91	30.73
Current Portion of Leases	6.28	12.9	7.78	12.59	5.06	6.28
Other Current Liabilities	4.36	6.75	2.44	6.51	4.86	4.34
Total Current Liabilities	125.79	122.34	110.31	91.49	89.2	54.87
Long-Term Debt	-	1	1	1	1	-
Long-Term Leases	45.21	44.37	67.09	71.86	65.47	45.38
Long-Term Deferred Tax Liabilities	31.67	32.32	17.35	-	-	-
Other Long-Term Liabilities	-	-	-	-	-	11.71
Total Liabilities	202.66	200.02	195.74	164.34	155.67	111.96
Common Stock	0.02	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	3,390	3,096	2,594	2,069	1,795	1,487
Retained Earnings	-2,704	-2,385	-2,012	-1,568	-1,172	-830.19
Comprehensive Income & Other	16.1	-1.05	2.53	-0.9	-0.6	0.02
Total Common Equity	702.29	710.4	584.61	499.64	621.66	656.49
Shareholders' Equity	702.29	710.41	584.61	499.64	621.66	656.5
Total Liabilities & Equity	904.95	910.43	780.35	663.98	777.33	768.46
Total Debt	52.49	58.26	75.86	85.45	71.53	51.66
Net Cash (Debt)	248.31	265.52	204.01	386.4	432.88	577.78
Net Cash Growth	-22.05%	30.15%	-47.20%	-10.74%	-25.08%	95.47%
Net Cash Per Share	0.75	0.92	0.87	2.43	2.82	4.18
Filing Date Shares Outstanding	396.97	327.88	279.31	224.24	157.17	146.98
Total Common Shares Outstanding	385.46	305.25	256.14	187.81	157	146.87
Working Capital	303.31	334.68	197.54	387.63	418.76	581.23
Book Value Per Share	1.82	2.33	2.28	2.66	3.96	4.47
Tangible Book Value	417.08	428	355.35	499.64	621.66	656.49
Tangible Book Value Per Share	1.08	1.40	1.39	2.66	3.96	4.47
Machinery	40.24	34.28	33.27	31.79	14.87	5.41
Construction In Progress	32.83	34.94	24.1	9.12	35.78	56.76
Leasehold Improvements	90.4	67.38	76.8	74.31	57.82	2.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.